Asia Pacific CAR-T Cell Therapy Market

Asia Pacific CAR-T Cell Therapy Market was estimated at USD 1.2 billion in 2025 and is projected to reach approximately USD 1.4 billion in 2026 and USD 3.6 billion by 2031, expanding at an estimated 20.9% CAGR during 2026-2031.

Description

The Asia Pacific CAR-T Cell Therapy Market was estimated at USD 1.2 billion in 2025 and is projected to reach approximately USD 1.4 billion in 2026 and USD 3.6 billion by 2031, expanding at an estimated 20.9% CAGR during 2026-2031. Growth is supported by rising cancer incidence, increasing adoption of cellular immunotherapies, expanding clinical-trial activity, and investment in regional cell-processing and manufacturing infrastructure. China remains the leading market, while India, Japan, South Korea, and Australia are strengthening domestic CAR-T ecosystems through regulatory development, local manufacturing, and research collaborations.

Table of Contents

  • Product Overview

    1. Market Definition

    2. Scope of the Market

      1. Markets Covered

      2. Years Considered for Study

      3. Key Market Segmentations

  • Research Methodology

    1. Objective of the Study

    2. Baseline Methodology

    3. Key Industry Partners

    4. Major Association and Secondary Sources

    5. Forecasting Methodology

    6. Data Triangulation & Validation

    7. Assumptions and Limitations

  • Executive Summary

    1. Overview of the Market

    2. Overview of Key Market Segmentations

    3. Overview of Key Market Players

    4. Overview of Key Regions/Countries

    5. Overview of Market Drivers, Challenges, Trends

  • Voice of Customer

  • Asia Pacific CAR-T Cell Therapy Market Outlook

    1. Market Size & Forecast

      1. By Value

    2. Market Share & Forecast

      1. By Therapy Type (Autologous CAR-T, Allogeneic CAR-T, Universal/Off-the-Shelf CAR-T)

      2. By Target Antigen (CD19, BCMA, CD22, Others)

      3. By Therapeutic Area (Hematologic Malignancies, Solid Tumors, Autoimmune Diseases, Others)

      4. By End User (Hospitals, Cancer Treatment Centers, Academic & Research Institutes)

      5. By Country

      6. By Company (2025)

  • China CAR-T Cell Therapy Market Outlook

    1. Market Size & Forecast

      1. By Value

    2. Market Share & Forecast

      1. By Therapy Type

      2. By Target Antigen

      3. By Therapeutic Area

      4. By End User

      5. By Region

  • India CAR-T Cell Therapy Market Outlook

    1. Market Size & Forecast

      1. By Value

    2. Market Share & Forecast

      1. By Therapy Type

      2. By Target Antigen

      3. By Therapeutic Area

      4. By End User

      5. By Region

  • Japan CAR-T Cell Therapy Market Outlook

    1. Market Size & Forecast

      1. By Value

    2. Market Share & Forecast

      1. By Therapy Type

      2. By Target Antigen

      3. By Therapeutic Area

      4. By End User

      5. By Region

  • Australia CAR-T Cell Therapy Market Outlook

    1. Market Size & Forecast

      1. By Value

    2. Market Share & Forecast

      1. By Therapy Type

      2. By Target Antigen

      3. By Therapeutic Area

      4. By End User

      5. By Region

  • Singapore CAR-T Cell Therapy Market Outlook

    1. Market Size & Forecast

      1. By Value

    2. Market Share & Forecast

      1. By Therapy Type

      2. By Target Antigen

      3. By Therapeutic Area

      4. By End User

      5. By Region

  • Market Dynamics

    1. Drivers

    2. Challenges

    3. Trends & Developments

  • Asia Pacific CAR-T Cell Therapy Market IP Overview

  • Asia Pacific CAR-T Cell Therapy Market: SWOT Analysis

  • Porter's Five Forces Analysis

    1. Competition in the Industry

    2. Potential of New Entrants

    3. Power of Suppliers

    4. Power of Customers

    5. Threat of Substitute Products

  • Competitive Landscape

    1. CARsgen Therapeutics

      1. Business Overview

      2. Products & Services

      3. Recent Developments

      4. Key Personnel

      5. SWOT Analysis

    2. JW Therapeutics

    3. Fosun Kite

    4. ImmunoACT

    5. Legend Biotech

    6. Novartis AG

    7. Gilead Sciences / Kite

    8. Bristol Myers Squibb

    9. Immuneel Therapeutics

    10. Nanjing IASO Biotherapeutics

  • Strategic Recommendations

  • About Us & Disclaimer

    • [Type here]

    Methodology